CGEN Mar 2025 2.500 call
| Previous close | 0.5500 |
| Open | 0.6000 |
| Bid | 0.1500 |
| Ask | 0.7500 |
| Strike | 2.50 |
| Expiry date | 2025-03-21 |
| Day's range | 0.6000 - 0.6800 |
| Contract range | N/A |
| Volume | |
| Open interest | 37 |
ZacksCompugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Compugen (CGEN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
PR NewswireCompugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it is entitled to receive a milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca's PD-1/TIGIT bispecific antibody. The TIGIT component of rilvegostomig is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902. Both rilvegostomi
Simply Wall St.Earnings Release: Here's Why Analysts Cut Their Compugen Ltd. (NASDAQ:CGEN) Price Target To US$5.00
Compugen Ltd. ( NASDAQ:CGEN ) just released its first-quarter report and things are looking bullish. Revenue crushed...
